1.65
+8.94%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Elicio Therapeutics
From its filings with the US Securities and Exchange Commission
Elicio Therapeutics is based in Boston, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ELTX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2022, it reported revenue of $2.3m.
We are a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mutant Kirsten rat sarcoma viral oncogene homolog (“mKRAS”) - positive pancreatic cancer, colorectal cancer (“CRC”), lung cancer and other mKRAS positive cancers. We intend to build on recent clinical successes in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Our proprietary Amphiphile (“AMP”) technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Recent advances have identified T cell responses as a key component of effective cancer immunotherapy and we believe our AMP technology can generate robust T cell responses in patients that can potentially translate to meaningful clinical benefit.
We believe the therapeutic utility of currently approved and development stage cancer immunotherapies is limited in many cases due to their inability to sufficiently localize to lymph nodes and adequately engage with the critical immune cells responsible for stimulating adaptive immunity. Our AMP technology is specifically intended to localize payloads to lymph nodes leading to the generation of a robust T cell response that we believe is critical to generate an anticancer immune response.
Quoted from its 10-K, filed 12 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 5 Feb 2021
- Employees
- 33
- Website
- elicio.com ↗
- Head office
- 451 D STREET, 5TH FLOOR, BOSTON, MA, 02210
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Dr. Julian AdamsIndependent Chairman of the Board$104,523
- Mr. Robert ConnellyPresident, Chief Executive Officer, Director, since 2023$2.0m
- Dr. Preetam ShahPrincipal Financial Officer, Principal Accounting Officer, Chief Strategy Officer
- Dr. Christopher HaqqExecutive Vice President, Head - Research and Development, Chief Medical Officer$926,452
- Dr. Peter DemuthChief Scientific Officer$866,671
- Dr. Jay VenkatesanDirector, since 2018$57,148
- Ms. Carol AsheIndependent Director$79,648
- Ms. Yekaterina ChudnovskyIndependent Director$60,717
- Dr. Allen NissensonIndependent Director$65,273
- Dr. Robert RuffoloIndependent Director$62,148
- Ms. Karen WilsonIndependent Director$77,148
- Mr. Carlo TanziInvestor Relations, since 2025
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Elicio Therapeutics' amphiphile (AMP) platform targets lymph nodes for immune therapy delivery.
- ELI-002 is in Phase I/II trials for KRAS-driven cancers with a focus on immunotherapy.
- The company's ELI-004 adjuvant is being tested for SARS-CoV-2 immune response induction.
Weaknesses
- Elicio Therapeutics has only 33 employees, indicating limited operational capacity.
- The company's lead product ELI-002 is still in early clinical trials without market approval.
- Elicio Therapeutics' business is focused on a single platform with limited diversification.
Opportunities
- The AMP platform could expand to treat additional diseases beyond cancer and infectious diseases.
- ELI-004's potential use in SARS-CoV-2 prevention offers a new market opportunity.
- The company's ALK program may identify new internal development candidates for future growth.
Threats
- Elicio Therapeutics faces competition from established biotech firms in the Health Care sector.
- Clinical trial delays could impact the timeline for ELI-002 and ELI-004 development.
- Regulatory hurdles may slow the approval process for new immunotherapies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.